Xiongbing Zu

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 7

Top Topics

Mesenchymal Stem Cells

Combination Therapy

Anti Inflammatory

Peripheral Blood

Top Venues

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Huihuang Li, Jinbo Chen, Zhenghao Li, Minfeng Chen, Zhenyu Ou, Miao Mo, Ruizhe Wang, Shiyu Tong, Peihua Liu, Zhiyong Cai, Chunyu Zhang, Zhi Liu, Dingshan Deng, Jinhui Liu, Chunliang Cheng, Jiao Hu, Xiongbing Zu
S100A5 Attenuates Efficiency of Anti-PD-L1/PD-1 Immunotherapy by Inhibiting CD8 + T Cell-Mediated Anti-Cancer Immunity in Bladder Carcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Zhiyong Cai, Jinbo Chen, Zhengzheng Yu, Huihuang Li, Zhi Liu, Dingshan Deng, Jinhui Liu, Chunliang Chen, Chunyu Zhang, Zhenyu Ou, Minfeng Chen, Jiao Hu, Xiongbing Zu
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 10 (8) (2023)
Zhiyong Cai, Jinbo Chen, Zhengzheng Yu, Huihuang Li, Zhi Liu, Dingshan Deng, Jinhui Liu, Chunliang Chen, Chunyu Zhang, Zhenyu Ou, Minfeng Chen, Jiao Hu, Xiongbing Zu
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Zhiyong Cai, Jinbo Chen, Zhengzheng Yu, Huihuang Li, Zhi Liu, Dingshan Deng, Jinhui Liu, Chunliang Chen, Chunyu Zhang, Zhenyu Ou, Minfeng Chen, Jiao Hu, Xiongbing Zu
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 10 (8) (2023)
Anze Yu, Jiao Hu, Liangmin Fu, Gaowei Huang, Dingshan Deng, Mingxiao Zhang, Yinghan Wang, Guannan Shu, Lanyu Jing, Huihuang Li, Xu Chen, Taowei Yang, Jinhuan Wei, Zhen-Hua Chen, Xiongbing Zu, Junghang Luo
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8 + T cell infiltration and functional transition. Journal for immunotherapy of cancer 11 (10) (2023)
Zhiyong Cai, Jinbo Chen, Zhengzheng Yu, Huihuang Li, Zhi Liu, Dingshan Deng, Jinhui Liu, Chunliang Chen, Chunyu Zhang, Zhenyu Ou, Minfeng Chen, Jiao Hu, Xiongbing Zu
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 10 (8) (2023)
Jiao Hu, Belaydi Othmane, Anze Yu, Huihuang Li, Zhiyong Cai, Xu Chen, Wenbiao Ren, Jinbo Chen, Xiongbing Zu
5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer. BMC medicine 19 (1) (2021)